{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T23:33:00Z","timestamp":1791761580317,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The government of Saga Prefecture."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00535-022-01942-z","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T13:02:33Z","timestamp":1671282153000},"page":"196-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9995-5522","authenticated-orcid":false,"given":"Toshihiko","family":"Kakiuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneaki","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaroh","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroharu","family":"Kawakubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Sumino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"key":"1942_CR1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1056\/NEJMoa001999","volume":"345","author":"N Uemura","year":"2001","unstructured":"Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784\u20139.","journal-title":"N Engl J Med"},{"key":"1942_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00535-017-1407-1","volume":"53","author":"H Suzuki","year":"2018","unstructured":"Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354\u201361.","journal-title":"J Gastroenterol"},{"key":"1942_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.chom.2014.02.008","volume":"15","author":"M Hatakeyama","year":"2014","unstructured":"Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15:306\u201316.","journal-title":"Cell Host Microbe"},{"key":"1942_CR4","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/1097-0142(19950615)75:12<2789::AID-CNCR2820751202>3.0.CO;2-4","volume":"75","author":"S Kikuchi","year":"1995","unstructured":"Kikuchi S, Wada O, Nakajima T, et al. Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Research group on prevention of gastric carcinoma among young adults. Cancer. 1995;75:2789\u201393.","journal-title":"Cancer"},{"key":"1942_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000339176","volume":"86","author":"S Ono","year":"2012","unstructured":"Ono S, Kato M, Suzuki M, et al. Frequency of Helicobacter pylori -negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion. 2012;86:59\u201365.","journal-title":"Digestion"},{"key":"1942_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1523-5378.2011.00889.x","volume":"16","author":"T Matsuo","year":"2011","unstructured":"Matsuo T, Ito M, Takata S, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415\u20139.","journal-title":"Helicobacter"},{"key":"1942_CR7","doi-asserted-by":"publisher","first-page":"dju116","DOI":"10.1093\/jnci\/dju116","volume":"106","author":"WQ Li","year":"2014","unstructured":"Li WQ, Ma JL, Zhang L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst. 2014;106:dju116.","journal-title":"J Natl Cancer Inst"},{"key":"1942_CR8","doi-asserted-by":"publisher","first-page":"g3174","DOI":"10.1136\/bmj.g3174","volume":"348","author":"AC Ford","year":"2014","unstructured":"Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.","journal-title":"BMJ"},{"key":"1942_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0140-6736(08)61159-9","volume":"372","author":"K Fukase","year":"2008","unstructured":"Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392\u20137.","journal-title":"Lancet"},{"key":"1942_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/hel.12146","volume":"19","author":"SB Yoon","year":"2014","unstructured":"Yoon SB, Park JM, Lim CH, et al. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter. 2014;19:243\u20138.","journal-title":"Helicobacter"},{"key":"1942_CR11","unstructured":"Latest cancer statistics. Ranking of cancer deaths in 2020. National Cancer Center Japan. 2022. https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html. Accessed 18 Oct 2022."},{"key":"1942_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00535-019-01559-9","volume":"54","author":"T Kakiuchi","year":"2019","unstructured":"Kakiuchi T, Matsuo M, Endo H, et al. A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report. J Gastroenterol. 2019;54:699\u2013707.","journal-title":"J Gastroenterol"},{"key":"1942_CR13","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00535-011-0450-6","volume":"46","author":"T Akamatsu","year":"2011","unstructured":"Akamatsu T, Ichikawa S, Okudaira S, et al. Introduction of an examination and treatment for Helicobacter pylori infection in high school health screening. J Gastroenterol. 2011;46:1353\u201360.","journal-title":"J Gastroenterol"},{"key":"1942_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s10120-017-0688-7","volume":"20","author":"C Kusano","year":"2017","unstructured":"Kusano C, Gotoda T, Ishikawa H, et al. The administrative project of Helicobacter pylori infection screening among junior high school students in an area of Japan with a high incidence of gastric cancer. Gastric Cancer. 2017;20:16\u20139.","journal-title":"Gastric Cancer"},{"key":"1942_CR15","doi-asserted-by":"publisher","first-page":"e12696","DOI":"10.1111\/hel.12696","volume":"25","author":"E Kaji","year":"2020","unstructured":"Kaji E, Yoden A, Otani M, et al. Helicobacter pylori test-and-treat strategy for second-year junior high school students aimed at the prevention of gastric cancer in Takatsuki City. Helicobacter. 2020;25:e12696.","journal-title":"Helicobacter"},{"key":"1942_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1128\/JCM.40.2.649-653.2002","volume":"40","author":"S Kato","year":"2002","unstructured":"Kato S, Fujimura S, Udagawa H, et al. Antibiotic resistance of Helicobacter pylori strains in Japanese children. J Clin Microbiol. 2002;40:649\u201353.","journal-title":"J Clin Microbiol"},{"key":"1942_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1442-200X.2009.02915.x","volume":"52","author":"S Kato","year":"2010","unstructured":"Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatr Int. 2010;52:187\u201390.","journal-title":"Pediatr Int"},{"key":"1942_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.gtc.2015.05.008","volume":"44","author":"T Akamatsu","year":"2015","unstructured":"Akamatsu T, Okamura T, Iwaya Y, et al. Screening to identify and eradicate Helicobacter pylori infection in teenagers in Japan. Gastroenterol Clin North Am. 2015;44:667\u201376.","journal-title":"Gastroenterol Clin North Am"},{"key":"1942_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pharmthera.2005.05.005","volume":"108","author":"K Andersson","year":"2005","unstructured":"Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005;108:294\u2013307.","journal-title":"Pharmacol Ther"},{"key":"1942_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719\u201330.","journal-title":"Aliment Pharmacol Ther"},{"key":"1942_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000504939","volume":"102","author":"S Shinozaki","year":"2021","unstructured":"Shinozaki S, Kobayashi Y, Osawa H, et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis. Digestion. 2021;102:319\u201325.","journal-title":"Digestion"},{"key":"1942_CR22","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439\u201346.","journal-title":"Gut"},{"key":"1942_CR23","doi-asserted-by":"publisher","first-page":"4385161","DOI":"10.1155\/2017\/4385161","volume":"2017","author":"M Maruyama","year":"2017","unstructured":"Maruyama M, Tanaka N, Kubota D, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol. 2017;2017:4385161.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1942_CR24","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s00535-017-1406-2","volume":"53","author":"C Kusano","year":"2018","unstructured":"Kusano C, Gotoda T, Suzuki S, et al. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children. J Gastroenterol. 2018;53:718\u201324.","journal-title":"J Gastroenterol"},{"key":"1942_CR25","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/ped.13286","volume":"59","author":"M Okuda","year":"2017","unstructured":"Okuda M, Mabe K, Lin Y, et al. Rapid urine antibody test for Helicobacter pylori infection in adolescents. Pediatr Int. 2017;59:798\u2013802.","journal-title":"Pediatr Int"},{"key":"1942_CR26","doi-asserted-by":"publisher","first-page":"e12329","DOI":"10.1111\/hel.12329","volume":"22","author":"K Mabe","year":"2017","unstructured":"Mabe K, Kikuchi S, Okuda M, et al. Diagnostic accuracy of urine Helicobacter pylori antibody test in junior and senior high school students in Japan. Helicobacter. 2017;22:e12329.","journal-title":"Helicobacter"},{"key":"1942_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000490889","volume":"99","author":"Y Takara","year":"2019","unstructured":"Takara Y, Endo H, Nakano R, et al. Smoking and drinking did not increase the failure of therapeutic Helicobacter pylori eradication by vonoprazan, clarithromycin, and amoxicillin. Digestion. 2019;99:172\u20138.","journal-title":"Digestion"},{"key":"1942_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/ajg.2016.182","volume":"111","author":"S Suzuki","year":"2016","unstructured":"Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111:949\u201356.","journal-title":"Am J Gastroenterol"},{"key":"1942_CR29","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1007\/s10620-017-4664-1","volume":"62","author":"H Tanabe","year":"2017","unstructured":"Tanabe H, Ando K, Sato K, et al. Efficacy of vonoprazan-based triple therapy for Helicobacter pylori eradication: a multicenter study and a review of the literature. Dig Dis Sci. 2017;62:3069\u201376.","journal-title":"Dig Dis Sci"},{"key":"1942_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000485097","volume":"97","author":"H Ozaki","year":"2018","unstructured":"Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion. 2018;97:212\u20138.","journal-title":"Digestion"},{"key":"1942_CR31","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s00535-004-1398-6","volume":"39","author":"S Kato","year":"2004","unstructured":"Kato S, Konno M, Maisawa S, et al. Results of triple eradication therapy in Japanese children: a retrospective multicenter study. J Gastroenterol. 2004;39:838\u201343.","journal-title":"J Gastroenterol"},{"key":"1942_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/hel.12124","volume":"19","author":"T Okamura","year":"2014","unstructured":"Okamura T, Suga T, Nagaya T, et al. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014;19:214\u201320.","journal-title":"Helicobacter"},{"key":"1942_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2036.2006.03236.x","volume":"25","author":"R Khurana","year":"2007","unstructured":"Khurana R, Fischbach L, Chiba N, et al. Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. Aliment Pharmacol Ther. 2007;25:523\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"1942_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2169\/internalmedicine.2521-18","volume":"59","author":"S Kiyotoki","year":"2020","unstructured":"Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med (Tokyo, Japan). 2020;59:153\u201361.","journal-title":"Intern Med (Tokyo, Japan)"},{"key":"1942_CR35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/MPG.0000000000001594","volume":"64","author":"NL Jones","year":"2017","unstructured":"Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN\/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;64:991\u20131003.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1942_CR36","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/ped.14388","volume":"62","author":"S Kato","year":"2020","unstructured":"Kato S, Shimizu T, Toyoda S, et al. The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood. Pediatr Int. 2020;62:1315\u201331.","journal-title":"Pediatr Int"},{"key":"1942_CR37","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019\u201326.","journal-title":"Gut"},{"key":"1942_CR38","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00535-020-01709-4","volume":"55","author":"T Gotoda","year":"2020","unstructured":"Gotoda T, Kusano C, Suzuki S, et al. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-na\u00efve cohort of junior high school students in Japan. J Gastroenterol. 2020;55:969\u201376.","journal-title":"J Gastroenterol"},{"key":"1942_CR39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000454762","volume":"94","author":"M Tsujimae","year":"2016","unstructured":"Tsujimae M, Yamashita H, Hashimura H, et al. A comparative study of a new class of gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of Helicobacter pylori. Digestion. 2016;94:240\u20136.","journal-title":"Digestion"},{"key":"1942_CR40","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jiac.2018.02.013","volume":"24","author":"K Mabe","year":"2018","unstructured":"Mabe K, Okuda M, Kikuchi S, et al. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. J Infect Chemother. 2018;24:538\u201343.","journal-title":"J Infect Chemother"},{"key":"1942_CR41","doi-asserted-by":"publisher","first-page":"e12575","DOI":"10.1111\/hel.12575","volume":"24","author":"M Okuda","year":"2019","unstructured":"Okuda M, Lin Y, Wang C, et al. Metronidazole for Helicobacter pylori eradication therapy among children and adolescents in Japan: overcoming controversies and concerns. Helicobacter. 2019;24:e12575.","journal-title":"Helicobacter"},{"key":"1942_CR42","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1086\/516306","volume":"26","author":"ME Falagas","year":"1998","unstructured":"Falagas ME, Walker AM, Jick H, et al. Late incidence of cancer after metronidazole use: a matched metro-nidazole user\/nonuser study. Clin Infect Dis. 1998;26:384\u20138.","journal-title":"Clin Infect Dis"},{"key":"1942_CR43","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1542\/peds.100.1.e3","volume":"100","author":"S Kato","year":"1997","unstructured":"Kato S, Takeyama J, Ebina K, et al. Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. Pediatrics. 1997;100:E3.","journal-title":"Pediatrics"},{"key":"1942_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/ped.13038","volume":"59","author":"M Okuda","year":"2017","unstructured":"Okuda M, Kikuchi S, Mabe K, et al. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. Pediatr Int. 2017;59:57\u201361.","journal-title":"Pediatr Int"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01942-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-022-01942-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01942-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T20:03:47Z","timestamp":1678392227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-022-01942-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1942"],"URL":"https:\/\/doi.org\/10.1007\/s00535-022-01942-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,17]]},"assertion":[{"value":"21 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest. This study received no financial support.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}